Major Depressive Disorder

This Year in Review features 2024 psychiatry highlights: FDA approvals, MDMA-assisted therapy setback, MM120 breakthrough, new CPT codes, and advances in schizophrenia treatments.

In a recent study, the prevalence of RLS occurred in 42.9% of participants with depression.

A study finds that therapists deliver high-quality CBT in routine psychiatric care but found no evidence that therapist adherence and competence correlate to patient outcomes.

America's mental health crisis continues to escalate—what drives it, and what lies ahead in 2025? Hear insight from psychiatry and psychology experts.

A study shows constipation has a causal relationship with schizophrenia and MDD, but the relationship with schizophrenia may have limited clinical implications.

A study found only 38% of patients in the large US academic health system screened for depression received antidepressants or mental health referrals.

A study found psilocybin therapy brings life-changing relief to depression symptoms triggered by clinicians’ frontline work during the COVID-19 pandemic.

A study revealed that people who are older, uneducated, unemployed, below the poverty line, publicly insured, rural, and male did not increase in psychotherapy use from 2018 to 2021.

Intra-Cellular Therapies announced they submitted a supplemental New Drug Application to the FDA for lumateperone (CAPLYTA) as an adjunctive therapy to antidepressants for MDD.

In part 1 of this 2-part discussion, hosts explore the ethical foundation and background of euthanasia and medically-assisted suicide.

In a recent phase 2a trial, SPN-820, a novel intracellular moderator of mTORC1, decreased suicidal ideation by 80%.

Alto Neuroscience's ALTO-100 failed to beat placebo in a phase 2b trial for depression, leading to a 60% stock drop.

In the complete response letter, the FDA classified deficiencies in the Abbreviated New Drug Application for ketamine as MINOR.

A study found that adding depression to Life's Essential 8 provides minimal improvements in predicting cardiovascular and all-cause mortality risk.

A new meta-analysis found elevated triglyceride levels in patients with major depressive disorder, potentially explaining the link between depression and cardiovascular risks.

A recent study shows the FDA's black-box warnings on antidepressants have led to decreased usage among youth, with an increase in suicide attempts and deaths observed.

A new study finds causal links between schizophrenia and MDD on IBS, highlighting the need for integrated care addressing both psychiatric and gastrointestinal symptoms.

Inpatients receiving brief cognitive behavioral therapy had a 60% reduced likelihood of suicide attempts and a 71% reduced rate of psychiatric readmissions post-discharge.

A report shows only 24%, 56%, and 62% of patients meet the criteria PSIL-AT for depression according to low-bound, mid-range, and upper-bound estimates, respectively.

A phase 3 trial found mirtazapine ineffective in reducing breathlessness in respiratory disease patients, urging caution with off-label antidepressant use.

A new study significantly demonstrated semaglutide, but not liraglutide, is associated with suicidal ideation.

Preliminary Phase 1b data demonstrated the favorable safety and tolerability profile of VLS-01 buccal film, with psychedelic effects resolved by 120 minutes.

A new study revealed an increased risk of psychiatric and autoimmune comorbidities after an alopecia areata diagnosis.

A recent study found a high prevalence of head injuries among law enforcement officers may make them more prone to experiencing mental health issues.

A new study found the group with the shortest seizure duration of ≤ 20 seconds had the lowest remission rate of 27.2%, compared with a 39.3% overall remission rate.